Primary hyperaldosteronism is a condition where the adrenal glands produce too much of a hormone called aldosterone, leading to high blood pressure that can be difficult to control with standard medications. Treatment aims to bring blood pressure under control, restore normal electrolyte balance, and reduce the risk of serious complications like heart attack, stroke, and kidney damage.
Why Managing Primary Hyperaldosteronism Matters
When people think about high blood pressure, they often assume it’s something that just happens with age or lifestyle. But for a significant number of patients—somewhere between 5% and 10% of all adults with high blood pressure—the real cause is hidden in two small glands sitting atop the kidneys. These adrenal glands are making too much aldosterone, a hormone that controls salt and water balance in the body. This overproduction pushes blood pressure higher and higher, and standard blood pressure medications often struggle to bring it down.[1]
The goals of treatment for primary hyperaldosteronism are clear and important. First, doctors aim to normalize blood pressure, which often requires specialized approaches rather than the usual medications. Second, treatment seeks to restore normal levels of potassium in the blood, as aldosterone excess causes the body to lose this vital mineral. Third, reducing aldosterone itself helps protect organs from damage. Finally, successful treatment can prevent life-threatening complications such as heart attacks, strokes, irregular heart rhythms, and kidney failure.[1]
Treatment choices depend heavily on what’s causing the excess aldosterone production. Some patients have a benign tumor on one adrenal gland that can be surgically removed. Others have both glands producing too much hormone, which requires lifelong medication. Still others have rare genetic forms that respond to different treatments. The stage of disease, the patient’s overall health, surgical risk, and individual preferences all play roles in deciding the best path forward.[2]
What makes primary hyperaldosteronism particularly dangerous is that it causes more organ damage than regular high blood pressure at the same blood pressure levels. Patients with this condition face a dramatically increased risk—up to 10 times higher—of serious cardiovascular events compared to people with the same blood pressure readings from other causes. This means that identifying and treating the condition properly isn’t just about lowering numbers on a blood pressure cuff; it’s about saving lives and preventing disability.[6]
Standard Medical Treatment Options
For patients who cannot have surgery or have both adrenal glands producing excess aldosterone—a condition called bilateral adrenal hyperplasia—medications form the cornerstone of treatment. The most important class of drugs used are mineralocorticoid receptor antagonists, which block the action of aldosterone at its target sites throughout the body. These medications don’t stop aldosterone production, but they prevent the hormone from causing harm.[7]
Two specific drugs dominate this treatment category. Spironolactone has been used for decades and remains the most commonly prescribed medication for primary hyperaldosteronism. It works by binding to the same receptors that aldosterone would normally attach to in the kidneys, heart, blood vessels, and other tissues. By occupying these receptors, spironolactone prevents aldosterone from causing sodium retention, potassium loss, and blood vessel damage. Doctors typically start with lower doses and gradually increase until blood pressure and potassium levels normalize. Many patients need additional blood pressure medications alongside spironolactone to achieve optimal control.[8]
The second major drug is eplerenone, which works similarly to spironolactone but is more selective in its action. Because eplerenone targets mineralocorticoid receptors more specifically, it causes fewer side effects related to sex hormones. Spironolactone can sometimes cause breast tenderness or enlargement in men and menstrual irregularities in women because it also affects androgen and progesterone receptors. Eplerenone avoids these problems, making it a preferred choice for some patients, though it’s generally more expensive.[11]
Clinical guidelines from medical societies strongly recommend mineralocorticoid receptor antagonists as the first-line medical therapy for patients with bilateral disease or those who cannot undergo surgery. These medications achieve remarkable blood pressure control and normalize plasma volume and serum potassium concentrations, particularly in patients with aldosterone-producing adenomas who are being prepared for surgery.[8]
Treatment duration with these medications is typically lifelong for patients with bilateral adrenal hyperplasia, since the underlying cause—overactive tissue in both glands—cannot be surgically corrected. Even patients who do have surgery may need to continue some blood pressure medications afterward, though often at lower doses or in fewer numbers than before. For patients being prepared for surgery, mineralocorticoid antagonists are usually started several weeks beforehand to control blood pressure and correct potassium levels, which reduces surgical risk.[8]
Like all medications, mineralocorticoid receptor antagonists can cause side effects. The most concerning is hyperkalemia, meaning potassium levels that climb too high. Since these drugs work partly by preventing potassium loss, they can sometimes overcorrect the problem. This is especially risky in patients with reduced kidney function, where the kidneys cannot clear excess potassium as effectively. Regular blood monitoring is essential, particularly when starting treatment or adjusting doses. Patients are usually advised to avoid high-potassium foods and potassium supplements unless specifically directed by their doctor.[8]
Other potential side effects of spironolactone include the hormone-related issues mentioned earlier—gynecomastia (breast enlargement) in men, breast tenderness, and menstrual irregularities in women. Some patients experience gastrointestinal upset, fatigue, or dizziness, especially when blood pressure drops quickly after starting treatment. Most side effects are mild and improve with dose adjustment or switching to eplerenone.[8]
Beyond mineralocorticoid antagonists, many patients require additional blood pressure medications to reach their target blood pressure. Combining spironolactone with thiazide diuretics often provides better blood pressure control than either drug alone. Other medication classes commonly used include calcium channel blockers, which relax blood vessels, and sometimes ACE inhibitors or angiotensin receptor blockers, though these must be used carefully because they can also raise potassium levels when combined with mineralocorticoid antagonists.[8]
There’s a special category of primary hyperaldosteronism called familial hyperaldosteronism type I, a rare genetic condition where both adrenal glands overproduce aldosterone due to an inherited gene abnormality. This form responds uniquely well to low doses of the steroid medication dexamethasone, which suppresses the abnormal hormone production. In these cases, dexamethasone can normalize blood pressure and electrolytes without the need for mineralocorticoid antagonists or surgery.[6]
Lifestyle modifications accompany medical treatment in all patients. Reducing salt intake is particularly important because aldosterone excess makes the body hold onto sodium, and dietary salt restriction can significantly improve blood pressure control even when aldosterone levels remain elevated. Weight loss, regular exercise, stress reduction, limiting alcohol, and avoiding certain substances like licorice (which can mimic aldosterone’s effects) all contribute to better outcomes.[13]
Surgical Treatment: Removing the Problem at Its Source
For patients with a single aldosterone-producing adenoma—a benign tumor on one adrenal gland—surgery offers the possibility of a cure. The procedure, called adrenalectomy, involves removing the affected adrenal gland. This is the preferred treatment approach when disease is confirmed to be coming from just one side, as it addresses the root cause rather than just managing symptoms with lifelong medication.[2]
Before surgery is recommended, doctors must confirm that aldosterone overproduction is truly coming from one gland and not both. This determination is made through a sophisticated procedure called adrenal venous sampling, where a radiologist threads thin tubes (catheters) into the veins draining each adrenal gland and takes blood samples directly from each side. By comparing aldosterone levels from the left and right adrenal veins, doctors can definitively identify which gland is the culprit. While CT scans can show tumors, they cannot always tell whether a visible tumor is actually producing aldosterone or whether both glands are secretly overactive despite only one showing a nodule on imaging.[4]
Modern adrenalectomy is most commonly performed using minimally invasive laparoscopic techniques. Surgeons make several small incisions and use specialized instruments and a camera to remove the gland. This approach causes less pain, requires shorter hospital stays, and allows faster recovery compared to traditional open surgery. Most patients spend just one or two nights in the hospital and can return to normal activities within a few weeks. The remaining adrenal gland on the opposite side takes over all necessary hormone production, so patients don’t need hormone replacement therapy after surgery.[4]
Surgery outcomes can be dramatic. Many patients experience complete resolution of their hypertension, meaning they no longer need any blood pressure medications at all. However, the cure rate varies depending on several factors. Patients who have had high blood pressure for many years, who are older, who have a family history of hypertension, or who needed many medications before surgery are less likely to be completely cured. Even so, nearly all patients experience significant improvement, often reducing from four or five blood pressure medications down to one or none.[4]
The average cure rate for hypertension after surgery for a single adenoma is approximately 33%, meaning about one-third of patients can stop all blood pressure medications completely. However, cure rates can be much higher in carefully selected patients—particularly younger individuals without a long history of hypertension. Even patients who aren’t completely cured almost always see substantial improvement in blood pressure control and can reduce their medication burden significantly.[8]
Before surgery, patients are typically treated with mineralocorticoid receptor antagonists for several weeks. This preoperative medical therapy serves two purposes: it controls blood pressure and corrects low potassium levels, both of which reduce the risk of complications during and after surgery. Patients continue their medications right up until the day of the procedure.[4]
After surgery, blood pressure often drops quickly, and medications may need to be reduced or stopped within days. Potassium levels, which may have been low before surgery, can actually rise too high after the aldosterone-producing tumor is removed, especially if patients are still taking potassium supplements or mineralocorticoid antagonists. Careful monitoring in the days and weeks after surgery allows doctors to adjust medications appropriately as the body recalibrates.[4]
Surgery carries risks, as do all operations. Bleeding, infection, and anesthesia complications are possible but uncommon. More specific to adrenalectomy is the small risk of damage to nearby organs like the spleen, kidney, pancreas, or major blood vessels. Experienced surgeons at specialized centers have very low complication rates. Patients who are not good surgical candidates—due to advanced age, severe heart or lung disease, or other major medical problems—are better treated with medication even if they have unilateral disease.[5]
For the relatively rare patient with adrenal cancer causing aldosterone overproduction, surgery is still the primary treatment, but the procedure is more extensive. Cancer requires removing the entire gland along with surrounding tissue and nearby lymph nodes. These operations are more complex and carry higher risks, but they offer the only chance for cure when the cancer is caught early and hasn’t spread to other organs.[5]
Emerging Treatments Being Studied in Clinical Trials
While mineralocorticoid receptor antagonists and surgery effectively treat most patients with primary hyperaldosteronism, researchers continue seeking better options. Clinical trials are exploring new medications, refined surgical techniques, and innovative approaches that might improve outcomes, reduce side effects, or offer alternatives for patients who don’t respond well to current treatments. These studies are happening in major medical centers across the United States, Europe, and other regions worldwide.
One area of active research involves developing next-generation mineralocorticoid receptor antagonists with improved properties. Current medications like spironolactone and eplerenone work well but aren’t perfect. Scientists are testing newer compounds that might block aldosterone’s harmful effects on the heart and blood vessels more effectively while causing fewer side effects. These experimental drugs are being evaluated in early-phase clinical trials (Phase I and Phase II) to determine whether they’re safe and whether they improve upon existing treatments.[11]
Research into the genetic causes of primary hyperaldosteronism has revealed that many aldosterone-producing adenomas contain mutations in genes that control ion channels—proteins that regulate the flow of charged particles like sodium, potassium, and calcium in and out of adrenal cells. Several specific mutations have been identified, and each causes cells to produce too much aldosterone through slightly different mechanisms. This discovery has opened the door to developing targeted therapies that address the specific molecular defect causing the disease.[6]
Scientists are particularly interested in mutations affecting calcium channels, potassium channels, and sodium-potassium pumps in adrenal cells. When these channels malfunction due to mutations, they disrupt the normal electrical balance in cells, which triggers excessive aldosterone production. Medications that correct these specific channel defects could theoretically treat aldosterone excess more precisely than current drugs, which work downstream by blocking aldosterone receptors rather than stopping excess production.[6]
Some research focuses on drugs that could shrink aldosterone-producing adenomas or reduce their hormone production without surgery. While no such medications are currently approved, various compounds are being studied in preclinical models. The idea is that if a drug could suppress tumor growth or aldosterone secretion directly, it might offer an alternative for patients who cannot or do not want surgery. These approaches are still in early research stages and would need extensive testing before reaching clinical use.
Clinical trials are also examining optimal treatment strategies for bilateral adrenal hyperplasia. While mineralocorticoid antagonists remain the standard therapy, questions remain about the best doses, whether combining multiple medications works better than maximizing one drug, and whether certain patients benefit from different treatment approaches. Some trials compare spironolactone at various doses against eplerenone to determine which medication offers better blood pressure control with fewer side effects in different patient populations.
Researchers continue refining diagnostic approaches to identify which patients have unilateral versus bilateral disease, since this distinction determines whether surgery is appropriate. Improved imaging techniques and more precise blood tests are being developed to make this determination more accurately without the need for the invasive adrenal venous sampling procedure, which requires specialized expertise and isn’t available at all medical centers. Better diagnostic tools could help more patients access appropriate surgical treatment.[12]
Some clinical studies are investigating whether interventional radiology techniques could treat aldosterone-producing adenomas without traditional surgery. One experimental approach involves threading a catheter to the blood vessels feeding the adenoma and blocking them off, essentially starving the tumor of blood supply. This ablation technique has shown promise in small studies but needs further research to prove it’s as effective as surgical removal. If successful, it could offer a less invasive option for patients who are poor surgical candidates.[11]
Understanding the cardiovascular damage caused by excess aldosterone has led to trials examining whether early and aggressive treatment can prevent or even reverse heart and blood vessel damage. Some studies are using sophisticated imaging techniques to measure changes in heart structure, blood vessel stiffness, and kidney function before and after treatment, helping researchers understand how quickly organs recover once aldosterone levels are controlled. This information helps doctors know how urgently to treat newly diagnosed patients.
Patient eligibility for clinical trials varies depending on the specific study. Generally, trials seek patients who have been recently diagnosed with primary hyperaldosteronism, have not yet started treatment, or are not achieving adequate control with current medications. Some studies specifically recruit patients with bilateral disease, while others focus on those preparing for surgery. Age restrictions, kidney function requirements, and other medical criteria differ between trials. Patients interested in participating should discuss options with their endocrinologist or visit clinical trial registries to find studies accepting participants in their region.
While these research efforts are promising, it’s important to understand that experimental treatments are not proven to work and may carry unknown risks. Clinical trials exist precisely to answer questions about safety and effectiveness that we don’t yet know. Participation in research helps advance medical knowledge and may offer access to potentially better treatments, but patients should make decisions with full understanding of what is established versus what is still being investigated.
Most Common Treatment Methods
- Mineralocorticoid Receptor Antagonists
- Spironolactone, taken as a daily pill, blocks aldosterone’s action at receptor sites throughout the body, controlling blood pressure and restoring normal potassium levels.[8]
- Eplerenone offers similar benefits to spironolactone with fewer hormone-related side effects, making it preferred for some patients despite higher cost.[11]
- These medications are the first-line treatment for patients with bilateral adrenal hyperplasia and for preparing surgical candidates before their operation.[7]
- Surgical Removal (Adrenalectomy)
- Laparoscopic removal of one adrenal gland cures or significantly improves hypertension in patients with a single aldosterone-producing adenoma.[4]
- The procedure is minimally invasive, typically requiring only a short hospital stay and offering relatively quick recovery.[4]
- Surgery is preferred for unilateral disease when adrenal venous sampling confirms one-sided aldosterone excess and patients are suitable surgical candidates.[2]
- Additional Blood Pressure Medications
- Thiazide diuretics, calcium channel blockers, and other antihypertensive agents are often used alongside mineralocorticoid antagonists to achieve optimal blood pressure control.[8]
- Combination therapy is frequently necessary, particularly before surgery or when blood pressure remains elevated despite mineralocorticoid antagonist therapy alone.[8]
- Glucocorticoid Therapy
- Low-dose dexamethasone effectively treats familial hyperaldosteronism type I, a rare genetic form of the disease that responds uniquely to steroid suppression.[6]
- Lifestyle Modifications
